Neurofibromatosis Program

Opportunities for Research Participation

Physicians and researchers from the Neurofibromatosis Program at Cincinnati Children’s offer clinical research studies for patients with neurofibromatosis.

View a complete list of current clinical trials or narrow your search specifically for those related to neurofibromatosis.

MEKINHIBITOR: A Phase I Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor
ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)
CLDK378X2103: A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies that have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
BRF116013: A Phase I/IIa, 2 Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Patients Aged 1 Month to <18 years with Advanced BRAF V600-Mutation Positive Solid Tumor

Find a Clinical Study

Find a clinical study specific to neurofibromatosis tumors. Using our database, you can narrow your search based on patient age, gender and condition. Find a Study

Neurofibromatosis Program

Neurofibromatosis Program

Opportunities for Research Participation

Find a Clinical Study

About Children's

Your Children's

Find Children's